Altmetric

CYFRA 21-1 predicts progression in IPF: a prospective longitudinal analysis of the PROFILE cohort

File Description SizeFormat 
Blue-202107-1769OC.R1_Clean.docxFile embargoed until 30 March 2023125.28 kBMicrosoft Word    Request a copy
Title: CYFRA 21-1 predicts progression in IPF: a prospective longitudinal analysis of the PROFILE cohort
Authors: Molyneaux, PL
Fahy, WA
Byrne, AJ
Braybrooke, R
Saunders, P
Toshner, R
Albers, G
Chua, F
Renzoni, EA
Wells, AU
Karkera, Y
Oballa, E
Saini, G
Nicholson, AG
Jenkins, G
Maher, TM
Item Type: Journal Article
Abstract: OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal condition for which there are a lack of effective biomarkers to guide therapeutic decision making. RATIONALE: To determine the relationship between serum levels of the cytokeratin fragment CYFRA 21-1 and disease progression and mortality in individuals with IPF enrolled in the PROFILE study. METHODS: CYFRA 21-1 was identified by immunohistochemistry in samples of human lung. Concentrations of CYFRA 21-1 were measured using an Elisa-based assay in serum, collected at baseline, 1- and 3-months, from 491 individuals with an incident diagnosis of IPF enrolled in the PROFILE study and from 100 control subjects. Study subjects were followed for a minimum of 3 years. MEASUREMENTS AND MAIN RESULTS: CYFRA 21-1 localises to hyperplastic epithelium in IPF lung. CYFRA 21-1 levels were significantly higher in IPF subjects compared to healthy controls in both discovery (n=132) (control 0.96±0.81 ng/mL versus IPF; 2.34±2.15 ng/mL, p < 0.0001) and validation (n=359) (control; 2.21±1.54 ng/mL and IPF; 4.13±2.77 ng/mL, p<0.0001) cohorts. Baseline levels of CYFRA 21-1 distinguished individuals at risk of 12-month disease progression (C-statistic 0.70 (95% CI 0.61-0.79), p < 0.0001) and were predictive of overall-mortality (HR 1.12 (1.06-1.19) per 1 ng/mL increase in CYFRA 21-1, p=0.0001). Furthermore, 3-month change in levels of CYFRA 21-1 separately predicted 12-month and overall survival in both the discovery and validation cohorts. CONCLUSIONS: CYFRA 21-1, a marker of epithelial damage and turnover, has the potential to be an important prognostic and therapeutic biomarker in individuals with IPF.
Issue Date: 15-Jun-2022
Date of Acceptance: 1-Apr-2022
URI: http://hdl.handle.net/10044/1/96287
DOI: 10.1164/rccm.202107-1769OC
ISSN: 1073-449X
Publisher: American Thoracic Society
Start Page: 1440
End Page: 1448
Journal / Book Title: American Journal of Respiratory and Critical Care Medicine
Volume: 205
Issue: 12
Copyright Statement: © 2022 by the American Thoracic Society
Sponsor/Funder: Action for Pulmonary Fibrosis
Funder's Grant Number: n/a
Keywords: biomarkers
clinical trials
epithelium
interstitial lung disease
biomarkers
clinical trials
epithelium
interstitial lung disease
Respiratory System
11 Medical and Health Sciences
Publication Status: Published
Conference Place: United States
Embargo Date: 2023-03-30
Online Publication Date: 2022-04-01
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine